Jason Harris

Senior Editor, OncLive®
Jason Harris has worked in journalism for more than 20 years, including stints at daily newspapers and niche publications for oncology and cardiology. He is a senior editor for OncologyLive® and managing editor for Oncology Fellows and the annual Giants of Cancer Care® album. He also contributes to the OncLive On Air and OncFellows podcasts. Email: jharris@onclive.com

Articles

Neoadjuvant, Adjuvant Immunotherapies Poised to Revolutionize Outcomes in Resectable NSCLC

February 5th 2022

Surgical resection remains the key treatment modality for early-stage non–small cell lung cancer; however, both systemic adjuvant and neoadjuvant therapeutics are options that have value for patients.

June Heralds CAR T-Cell Therapy as a “Cure” for CLL

February 2nd 2022

Treatment with CD19-specific CAR T cells resulted in durable remission lasting more than 10 years for 2 patients with chronic lymphocytic leukemia.

Nivolumab/Cabozantinib Combo Improves Patient-Reported Outcomes Over Sunitinib in RCC

January 26th 2022

The combination of nivolumab and cabozantinib was associated with improved quality of life compared with sunitinib in patients with previously untreated advanced renal cell carcinoma, according to patient-reported outcome data from the phase 3 CheckMate-9ER trial.

Nivolumab/Chemo Combo Maintains Clinical Efficacy at 2 Years in Gastric/GEJ Cancer

January 21st 2022

Nivolumab plus chemotherapy demonstrated a durable survival benefit for patients with gastric or gastroesophageal junction cancer, according to updated findings from the CheckMate 649 trial.

Activating the Immune System Could be Key to Treating Pediatric Neuroblastoma

January 11th 2022

Chemoimmunotherapy is still a relatively new strategy for patients with pediatric neuroblastoma, and the humanized anti-disialoganglioside monoclonal antibody hu14.18K322A could provide a breakthrough for children with high-risk disease.

Finding Focus in Fellowship

December 26th 2021

Leslie S. Kersun, MD, MSCE, MSEd, discusses finding the right fellowship program; the challenge of balancing research, patient care, and education as a trainee; and finding one’s focus during fellowship.

Putting the Extremely Rare Cardiac Angiosarcoma in the Spotlight

December 21st 2021

Cardiac angiosarcoma is an exceptionally rare cancer that has become national news because of the recent death of acclaimed fashion designer, Virgil Abloh. He was 41 years old when he died in November 2021, following a 2-year battle with the disease, which is an aggressive subtype of soft-tissue sarcoma.

Serum Ferritin Predicts Treatment Response in Myelofibrosis for Those Assigned to Momelotinib

December 14th 2021

Serum ferritin at baseline was a predictor for week 24 transfusion independence response in patients with myelofibrosis receiving momelotinib according to findings from an analysis of data from the phase 3 SIMPLIFY trials.

Sabatolimab Demonstrates Durable Clinical Benefits in Patients With AML, High-Risk MDS

December 14th 2021

Sabatolimab, an investigational TIM-3 monoclonal antibody, induced a median duration of response greater than 1 year for patients with very high/high-risk myelodysplastic syndrome and acute myeloid leukemia when used in combination with hypomethylating agents.

Acalabrutinib Improves PFS, Safety in Untreated CLL

December 13th 2021

Acalabrutinib, with or without obinutuzumab, induced a significant efficacy benefit for patients with treatment-naïve chronic lymphocytic leukemia compared with ibrutinib or venetoclax plus obinutuzumab, according to findings presented during the 63rd ASH Annual Meeting and Exposition.

Axi-Cel Demonstrates Ongoing Survival Benefit in Relapsed/Refractory iNHL

December 11th 2021

Axicabtagene ciloleucel induced high response rates and improved survival in patients with relapsed/refractory follicular lymphoma or marginal zone lymphoma, according to updated data from the phase 2 ZUMA-5 trial.

Neratinib Combos Show Promise in HER2-Mutant Metastatic Breast Cancers

December 10th 2021

Neratinib (Nerlynx) induced positive overall response rates in patients with heavily pretreated hormone receptor–positive/HER2-negative, HER2-mutant metastatic breast cancer when combined with fulvestrant and trastuzumab, and also in patients with metastatic HER2-mutant triple-negative breast cancer when combined with trastuzumab.

Early Use of ctDNA Testing Can Identify Likelihood of Relapse in TNBC

December 9th 2021

Physicians treating patients with early-stage triple-negative breast cancer should employ circulating tumor DNA testing early and often, according to results from the phase 2 cTRAK TN trial.

FDA Grants 510K Clearance to Exablate System for Prostate Cancer

December 6th 2021

The FDA has awarded 510K clearance to the Exablate Prostate system for the treatment of prostate cancer.

Investigators Still Working to Understand the Causes of Rare Gastric Cancer

December 1st 2021

Investigators have known about hereditary diffuse gastric cancer syndrome for decades, but only identified its molecular causes in the 1990s, said gastrointestinal oncologist Bryson Katona, MD, PhD.

AACR Backs Biden’s Nominee for FDA Commissioner

November 16th 2021

The American Association for Cancer Research issued a statement today congratulating Robert Califf, MD, on his nomination to be the next FDA commissioner. The association “strongly supports” his return to the agency.

Patients with RCC, Melanoma Taking ICIs Can Safely Receive COVID-19 Vaccination

November 15th 2021

The COVID-19 vaccine was safe and well tolerated in patients who received immune checkpoint inhibitors for renal cell carcinoma or melanoma.

Telotristat Ethyl Improves Symptoms and Patient Satisfaction in Carcinoid Syndrome

November 15th 2021

Patients with carcinoid syndrome reported improved symptoms following treatment with telotristat ethyl.

Surufatinib Induces Robust Responses in US Patients with Extrapancreatic and Pancreatic NETs

November 12th 2021

Surufatinib demonstrated strong antitumor activity along with a manageable safety profile in heavily treated US patients with progressive extrapancreatic neuroendocrine tumors or pancreatic NETs, according to interim phase 1 data.

Up-front Surgery, Biologics Do Not Improve Survival in Resectable CRC With Liver Metastases

November 11th 2021

Chemotherapy has demonstrated mixed findings in patients with resectable colorectal hepatic metastases, and long-term data suggest incorporating it into treatment algorithms have little impact on overall survival.